| 0.716 -0.04 (-5.25%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.96 | 1-year : | 1.05 |
| Resists | First : | 0.82 | Second : | 0.89 |
| Pivot price | 0.75 |
|||
| Supports | First : | 0.69 | Second : | 0.58 |
| MAs | MA(5) : | 0.75 |
MA(20) : | 0.76 |
| MA(100) : | 0.82 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 31.3 |
D(3) : | 39.5 |
| RSI | RSI(14): 38.8 |
|||
| 52-week | High : | 1.84 | Low : | 0.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ZTEK ] has closed above bottom band by 4.2%. Bollinger Bands are 64.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.75 - 0.75 | 0.75 - 0.76 |
| Low: | 0.7 - 0.7 | 0.7 - 0.71 |
| Close: | 0.71 - 0.71 | 0.71 - 0.72 |
Zentek Ltd. engages in the research and development of graphene and related nanomaterials in Canada. It owns 100% interest in the Albany Graphite project located in Northern Ontario, Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compound. In addition, it develops synthesize graphene, graphene oxide, and graphene quantum dots for applications of graphene. The company was formerly known as ZEN Graphene Solutions Ltd. and changed its name to Zentek Ltd. in October 2021. Zentek Ltd. was incorporated in 2008 and is headquartered in Thunder Bay, Canada.
Tue, 25 Nov 2025
Zentek Ltd. (Nasdaq: ZTEK) appoints Mohammed Jiwan CEO and issues 475K options, 425K RSUs - Stock Titan
Sat, 15 Nov 2025
Zentek Ltd. Reports Financial Results for Q3 2025 - The Globe and Mail
Wed, 22 Oct 2025
Zentek Announces Closing of Non-Brokered Private Placement of Units for Gross Proceeds of $2,479,227 - Newsfile
Tue, 07 Oct 2025
This trade activity should not be overlooked: Zentek Ltd (ZTEK) - Setenews
Wed, 27 Aug 2025
Nasdaq Warning: Zentek Has 180 Days to Boost Share Price Above $1 or Face Potential Delisting - Stock Titan
Wed, 27 Aug 2025
Zentek Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 0 (M) |
| Shares Float | 107 (M) |
| Held by Insiders | 1.0229e+008 (%) |
| Held by Institutions | 5.4 (%) |
| Shares Short | 115 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.24e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -36 % |
| Return on Assets (ttm) | 955.1 % |
| Return on Equity (ttm) | -28.1 % |
| Qtrly Rev. Growth | 915320 % |
| Gross Profit (p.s.) | -118.63 |
| Sales Per Share | -106.2 |
| EBITDA (p.s.) | 767902 |
| Qtrly Earnings Growth | -0.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 3.31 |
| Dividend | 0 |
| Forward Dividend | 93080 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|